| MORPHOSYS AG Patent applications |
| Patent application number | Title | Published |
|---|
| 20120129717 | Collection and Methods For Its Use - The present disclosure enables collections of variable heavy chain and variable light chain pairs comprising, in part, germline protein sequences that are pre-selected for functional properties relevant to developability, wherein the collections may be used to select against any antigen using, for example, phage display. | 05-24-2012 |
| 20120116059 | Treatment For MTreatment For Multiple Sclerosis - The present invention relates to methods for the treatment and/or prophylaxis of multiple sclerosis (MS). Antagonists of GM-CSF, such as antibodies specific for GM-CSF or the GM-CSF receptor, are effective in the treatment and/or prophylaxis of multiple sclerosis. | 05-10-2012 |
| 20120114659 | Antibodies for Guanylyl Cyclase Receptors - Monoclonal antibodies that act as potentiators, stimulators and agonists of guanylyl cyclase receptors are disclosed. | 05-10-2012 |
| 20120077713 | Collection and Methods for its Use - The present disclosure enables methods of identifying the VH and VL class pairs in the human immune repertoire, determining the VH and VL class pairs that are most prevalent and those having favorable biophysical properties. More specifically, the collections of the present disclosure comprise the most prevalent and/or preferred VH and VL class pairings with highly diversified CDRs. | 03-29-2012 |
| 20120028302 | Production of oligoclonal mixtures of immunoglobulins in single cells - The present invention provides methods to produce mixtures of exogenous proteins in single cells. Preferably said exogenous proteins are heteromeric and multimeric proteins, such as immunoglobulins. The method enables the controlled expression of proteins, thereby allowing the correct formation and assembly of multimeric proteins, such as immunoglobulins. | 02-02-2012 |
| 20110200589 | DECONVOLUTION METHOD - The present invention relates generally to novel applications in combating infectious disease, cancer, allergy and autoimmune diseases. In one aspect, the invention relates to identifying one or more protein binding moieties of interest. In another aspect, the present invention relates to identifying one or more candidate vaccines. | 08-18-2011 |
| 20110110944 | ANTI-ALK1 ANTIBODIES AND USES THEREOF - The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for AIk1, which plays an integral role in various disorders or conditions, such as cancer and macular degeneration. These antibodies, accordingly, can be used to treat these and other disorders and conditions. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of AIk1 in the progression of disorders associated with pathogenic angiogenesis. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use. | 05-12-2011 |
| 20100330577 | METHODS FOR IDENTIFICATION OF AN ANTIBODY OR A TARGET - This disclosure relates to methods for identifying an antibody, a target molecule, or an agent by analyzing the immunoglobulin repertoire sequence data in a sample and by determining the most dominant VH and VL chains present in said sample, as well as materials used therewith. | 12-30-2010 |
| 20100317546 | Display Vectors and Methods and Uses Thereof - The present invention relates, in one aspect, to a vector comprising (a) a first polynucleotide capable of encoding a first (poly)peptide comprising at least one cysteine residue, and (b) a second polynucleotide capable of encoding a second (poly)peptide which is a cell surface anchor comprising at least one cysteine residue, wherein the vector is operable in a eukaryotic host cell to express and to cause or allow the attachment of said first (poly)peptide to said second (poly)peptide by formation of a disulfide bond between said cysteine residues comprised within said first (polypeptide and said second (poly)peptide, respectively, wherein said first (poly)peptide is exhibited at the surface of a eukaryotic host cell. | 12-16-2010 |
| 20100291078 | Proteinaceous binding molecules comprising purification tags or inert variable domains - The present invention provides proteinaceous binding molecules, in particular antibodies, having at least two variable domains. One variable domain binds to a target molecule of interest. At least one other variable domain comprises a purification tag suitable for purification of said proteinaceous binding molecule. The purification tag enables the convenient purification of the proteinaceous binding molecule with monovalent binding properties against the target molecule. | 11-18-2010 |
| 20100190234 | METHODS FOR THE FORMATION OF DISULPHIDE BONDS - The present invention relates to methods for the formation of inter-molecular disulphide bonds, including (poly)peptides/proteins, nucleic acids, vectors, host cells and bacteriophages used in these methods. Furthermore the invention relates to the use of this method for the improved display of (poly)peptides/proteins on the surface of bacteriophage particles. | 07-29-2010 |
| 20100016553 | Internalization - A target internalized within a cell (and a binding member that specifically binds thereto) can be identified in an efficient manner by segregating (or substantially segregating) genetic material encoding the binding member from genetic material encoding a binding member that binds to a target that is not internalized. This can be achieved by employing a display library of binding members having a genotype/phenotype linkage via a non-fusion protein format, whereby genetic material encoding non-in-ternalized targets can be segregated (or substantially segregated) without lysing the cells. Internalized genetic material subsequently can be isolated and amplified. | 01-21-2010 |
| 20090252733 | Generation and Profiling of Fully Human Gold-Derived Therapeutic Antibodies Specific for Human CD38 - The present invention provides novel antibodies and methods for using recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These methods take advantage of newly discovered antibodies and surprising properties of such antibodies, such as the ability to bind CD38 of minipig origin and the ability to induce, by cross-linking, specific killing of cells that express CD38. These antibodies as well as the novel methods for using those antibodies can be used to treat, for example, hematological malignancies such as multiple myeloma. | 10-08-2009 |
| 20090123950 | Generation And Profiling Of Fully Human Hucal Gold.RTM.-Derived Therapeutic Antibodies Specific For Human CD38 - The present invention provides novel methods for using recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These methods take advantage of newly discovered antibodies and surprising properties of such antibodies, such as the ability to bind CD38 of minipig origin and the ability to induce, by cross-linking, specific killing of cells that express CD38. These antibodies as well as the novel methods for using those antibodies can be used to treat, for example, hematological malignancies such as multiple myeloma. | 05-14-2009 |
| 20090088346 | NOVEL COLLECTION OF HCDR3 REGIONS AND USES THEREFOR - The present invention is directed to the preparation and use of a collection of antibody heavy chain complementarity determining region 3 (HCDR | 04-02-2009 |
| 20090053213 | Anti-Gm-Csf Antibodies and Uses Therefor - The present invention provides recombinant antigen-binding regions, antibodies and functional fragments thereof that are specific for GM-CSF, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, inflammatory diseases such as rheumatoid arthritis. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of GM-CSF in the progression of various disorders. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use. | 02-26-2009 |
